A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Teva is developing laquinimod tablets as a new oral treatment for MS. Laquinimod has
immunomodulating properties. In a previous clinical study laquinimod showed evidence of
biological activity by reducing the number of acute brain lesions.
The duration of the current study is 36 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries